Enantiomerically pure opioid diarylmethylpiperzine and methods of using same
View Patent ↗An essentially pure compound of the formula: (−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof, having utility as a receptor-binding species, e.g., as a therapeutic agent for mediating analgesia; as a co-administered agent with various other bioactive compositions, including anesthetics, barbiturates, analgesics, etc.; for reducing, treating, reversing or preventing drug-mediated respiratory depression that may be directly or indirectly caused by use of such various bioactive compositions; as a conjugate in agonist/antagonist pairs for verifying/assaying receptor and neurotransmitter function; and as a therapeutic agent having utility in combating pain, cardiac disorders, mental and emotional disorders cough, diarrhea and gastro-intestinal disorders.
1. An essentially pure compound of the formula:
(−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof.
2. (−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof having an enantiopurity of at least 98%.
3. (−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof having an enantiopurity of at least 99%.
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier therefor.
5. A pharmaceutical composition comprising:
(a) an effective amount of a bioactive agent for treatment of a condition selected from the group consisting of drug addiction, alcohol addiction, drug overdose, mental illness, cough, lung edema, gastro-intestinal disorders, arthritis, psoriasis, asthma, inflammatory bowel disease, disorders of respiratory function, functional bowel disease, irritable bowel syndrome, diarrhea, functional distension, functional pain, non-ulcerogenic dyspepsia, organ transplant rejection, skin graft rejection, cardiac disorders, mental disorders, emotional disorders, cognitive disorders; emesis; respiratory depression; acne and skin lesions; and
(b) an effective amount of a compound comprising the formula:
(−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof.
6. A method of treating pain in an animal which comprises administering to an animal an effective amount of a compound of claim 1 .
7. The method of claim 6 , wherein the animal is a human.
8. The method of claim 6 , wherein the compound is administered by a mode of administration selected from the group consisting of parenteral, non-parenteral, oral, rectal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intrathecal, intra-articular, intra-arterial, sub-arachnoid, sublingual, oral mucosal, bronchial, lymphatic, and intra-uterine administration.
9. A method of effecting a receptor-mediated analgesia of an animal in need of same comprising administering to the animal an effective amount of the compound of claim 1 .
10. A method for treatment of one or more conditions selected from the group consisting of cough, functional diarrhea, and functional pain, comprising administration to a subject in need of such treatment an effective amount of a compound of claim 1 .
11. A method of reducing, treating or preventing drug-mediated respiratory depression in an animal caused by a mu opioid receptor binding agent, comprising:
administering to the animal a pharmaceutical composition comprising:
(1) an effective amount of a mu opioid receptor binding agent that acts on mu opioid receptors and has a respiratory depression side effect, and
(2) an effective amount of a compound of the formula:
(−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof, wherein the compound acts to attenuate the respiratory depression side effect of the mu opioid receptor binding agent without precluding the therapeutic efficacy of the mu opioid receptor binding agent.
12. The method according to claim 11 , wherein the mu opioid receptor binding agent is selected from the group consisting of anesthetics and analgesics.
13. The method according to claim 11 , wherein the mu opioid receptor binding agent comprises an analgesic agent selected from the group consisting of morphine, alfentanil, morphine-6-glucoronide, oxymorphone, hydromorphone, oxycodone, hydrocodone, fentanyl, meperidine, sufentanyl and codeine.
14. A method for screening opioid respiratory depression-suppressing compounds, comprising conducting activity reversal assays of a candidate respiratory depression-suppressing compound in receptor tissue to determine if the candidate respiratory depression-suppressing compound transductionally mediates a respiratory depression suppressing effect in the receptor tissue, in response to a respiration-depressing composition, wherein said activity reversal assays are conducted comparatively, in the absence and in the presence of an anti-suppression compound of the formula:
(−)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol or a pharmaceutically acceptable salt thereof, to determine if the activity of the candidate compound is substantially reversed at the tissue site by the presence of the anti-suppression compound of formula (I), thereby indicating the candidate respiratory depression-suppressing compound as possessing potential bioefficacy for suppressing respiratory depression effects incident to the use of other therapeutic agents.
15. A method of effecting a receptor-mediated analgesia of an animal in need of same without inducing nausea or vomiting comprising administering to the animal an effective amount of the compound of claim 1 to effect receptor-mediated analgesia without inducing nausea or vomiting.
16. The method according to claim 15 , wherein the animal is a human.
17. A method of effecting a receptor-mediated response of an animal in need of same comprising administering to the animal an effective amount of the compound of claim 1 to effect receptor-mediated response without inducing nausea or vomiting, wherein the opioid receptor-mediated response is selected from the group consisting of analgesia, reduced coughing, reduced functional pain and reduced functional diarrhea.
18. The compound according to claim 1 , further comprising a pharmaceutically acceptable ester of formula I wherein the ester is selected from the group consisting of:
a) carboxylic acid esters of the hydroxyl group of the compound of formula (I) wherein a non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl, alkoxyalkyl, arylalkyl, aryloxyalky, aryl;
b) amino acid esters;
c) dicarboxylic acid esters; and
d) carbonate esters; carbamate esters; and inorganic esters.